CD79a antibody

Catalog No. ABIN7880034

The Mouse Monoclonal anti-CD79a antibody is suitable to detect CD79a in samples from Human. It has been validated for FACS, IF and IHC (p).

Quick Overview for CD79a antibody (ABIN7880034)

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD79a antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: ZL7-4

Product Details anti-CD79a Antibody

Purpose: CD79a Antibody (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: IgM complex isolated from Daudi cells was used as the immunogen for this CD79a antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the CD79a antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the CD79a antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for CD79a

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Alternative Name: CD79a

Background: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

UniProt: P11912

Pathways: BCR Signaling